Hutchmed (China) Limited

Net Asset Value • Jun 4, 2014

National Storage Mechanism | Additional information

You don't have Javascript enabled. For full functionality this page requires javascript to be enabled.

RNS Number : 8479I

Hutchison China Meditech Limited

04 June 2014

Hutchison China MediTech Limited ("Chi-Med")

(AIM: HCM)

Director's Shareholding

London: Wednesday, 4 June 2014: Chi-Med received notification on 3 June 2014 that Mr Christopher Nash, Independent Non-executive Director of Chi-Med, purchased 4,036 ordinary shares of US$1.00 each in Chi-Med (the "Shares") at a price of GBP8.42 each on

3 June 2014.

Following this purchase, Mr Nash is beneficially interested in 30,542 Shares, representing approximately 0.06% of the current issued share capital of Chi-Med.

Ends

Enquiries

Chi-Med     Christian Hogg, CEO	Telephone:      +852 2121 8200
Panmure Gordon (UK) Limited     Richard Gray     Andrew Potts	Telephone:      +44 20 7886 2500
Citigate Dewe Rogerson     Anthony Carlisle     David Dible	Telephone:      +44 20 7638 9571 Mobile:             +44 7973 611 888 Mobile:             +44 7967 566 919

About Chi-Med

Chi-Med is a China-based healthcare group focused on researching, developing, manufacturing and selling pharmaceuticals and health-related consumer products.  Its China Healthcare Division manufactures, markets and distributes prescription and over-the-counter pharmaceuticals in China.  Its Drug R&D Division focuses on discovering and developing innovative therapeutics in oncology and autoimmune diseases.  Its emerging Consumer Products Division focuses on organic and natural consumer products in Asia.

Chi-Med (LSE:HCM) is majority owned by the multinational conglomerate Hutchison Whampoa Limited (SEHK:13).  For more information, please visit: www.chi-med.com.

This information is provided by RNS

The company news service from the London Stock Exchange

END

MSCSSFFELFLSEIM